-
Research funding: None declared.
-
Author contributions: All the authors contributed substantially to the conception of the work, the acquisition, analysis, or interpretation of data included in this study. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The study was carried out according to the Declaration of Helsinki. The patient referred in our letter is one of the authors.
References
1. Ferraro, S, Bussetti, M, Bassani, N, Rossi, RS, Incarbone, GP, Bianchi, F, et al.. Definition of outcome-based prostate-specific antigen (PSA) thresholds for advanced prostate cancer risk prediction. Cancers 2021;13:3381–95. https://doi.org/10.3390/cancers13143381.Search in Google Scholar
2. Pisansky, TM, Thompson, IM, Valicenti, RK, D’Amico, AV, Selvarajah, S. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA Guideline Amendment 2018–2019. J Urol 2019;202:533–8. https://doi.org/10.1097/ju.0000000000000295.Search in Google Scholar
3. Stish, BJ, Pisansky, TM, Harmsen, WS, Davis, BJ, Tzou, KS, Choo, R, et al.. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol 2016;34:3864–71. https://doi.org/10.1200/jco.2016.68.3425.Search in Google Scholar
4. Tendulkar, RD, Agrawal, S, Gao, T, Efstathiou, JA, Pisansky, TM, Michalski, JM, et al.. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 2016;34:3648–54. https://doi.org/10.1200/jco.2016.67.9647.Search in Google Scholar
5. Zaorsky, NG, Calais, J, Fanti, S, Tilki, D, Dorff, T, Spratt, DE, et al.. Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol 2021;18:643–68. https://doi.org/10.1038/s41585-021-00497-7.Search in Google Scholar
6. Perera, M, Papa, N, Roberts, M, Williams, M, Udovicich, C, Vela, I, et al.. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2020;77:403–17. https://doi.org/10.1016/j.eururo.2019.01.049.Search in Google Scholar
7. Semjonow, A, Brandt, B, Oberpenning, F, Roth, S, Hertle, L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 1996;7:3–16. https://doi.org/10.1002/(sici)1097-0045(1996)7+<3::aid-pros1>3.0.co;2-t.10.1002/(SICI)1097-0045(1996)7+<3::AID-PROS1>3.3.CO;2-5Search in Google Scholar
8. Stephan, C, Klaas, M, Muller, C, Schnorr, D, Loening, SA, Jung, K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52:59–64. https://doi.org/10.1373/clinchem.2005.059170.Search in Google Scholar
9. Boegemann, M, Arsov, C, Hadaschik, B, Herkommer, K, Imkamp, F, Nofer, JR, et al.. Discordant prostate specific antigen test results despite WHO assay standardization. Int J Biol Markers 2018;33:275–82. https://doi.org/10.1177/1724600818754750.Search in Google Scholar
10. Filella, X, Albaladejo, MD, Allue, JA, Castano, MA, Morell-Garcia, D, Ruiz, MA, et al.. Prostate cancer screening: guidelines review and laboratory issues. Clin Chem Lab Med 2019;57:1474–87. https://doi.org/10.1515/cclm-2018-1252.Search in Google Scholar
11. Ferraro, S, Bussetti, M, Rizzardi, S, Braga, F, Panteghini, M. Verification of Harmonization of serum total and free prostate-specific antigen (PSA) measurements and implications for medical decisions. Clin Chem 2021;67:543–53. https://doi.org/10.1093/clinchem/hvaa268.Search in Google Scholar PubMed
12. Ferraro, S, Biganzoli, EM. The clinical value of assessing the inter-method bias: the lesson from prostate specific antigen measurement. Clin Chem Lab Med 2021;60:149–51. https://doi.org/10.1515/cclm-2021-1125.Search in Google Scholar PubMed
13. Ferraro, S, Biganzoli, G, Bussetti, M, Castaldi, S, Biganzoli, EM, Plebani, M. Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management. Clin Chem Lab Med 2023;61:142–53. https://doi.org/10.1515/cclm-2022-0874.Search in Google Scholar PubMed
© 2023 Walter de Gruyter GmbH, Berlin/Boston
